Skip to main content
Assets
CRISPR Therapeutics logo
CRSP.NASDAQ
CRISPR Therapeutics
Health Care · Biotechnology

Gene editing company developing transformative therapies using CRISPR/Cas9 technology for genetic diseases and cancer.

HQ: SwitzerlandListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for CRISPR Therapeutics.

Historical AI Forecasts

CRISPR Therapeutics AG (CRSP.NASDAQ) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+219.1%

CRSP.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

CRISPR Therapeutics successfully executes a steady, albeit challenging, commercial launch for . Revenue growth is consistent but moderated by logistical and reimbursement hurdles, establishing a solid foundation. The company prudently manages its while advancing its pipeline. One of its next-generation immuno-oncology candidates shows positive data and progresses to a pivotal trial, de-risking the pipeline and providing a secondary value driver. The in-vivo programs advance methodically, showing promise but not yet reaching a major inflection point within this timeframe. The stock price appreciates, reflecting the gradual transition from a clinical-stage to a commercial-stage company with a validated platform. The valuation grows based on tangible revenue and increasing probability of success for one to two pipeline assets, avoiding both extreme euphoria and excessive pessimism.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.15.9365.28114.62163.96213.31Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2020-11-23110
Observed price2020-12-13151
Observed price2021-01-02156
Observed price2021-01-14197
Observed price2021-01-18194
Observed price2021-02-11159
Observed price2021-02-15156
Observed price2021-03-07114
Observed price2021-03-15131
Observed price2021-03-27112
Observed price2021-04-28136
Observed price2021-05-06108
Observed price2021-05-10101
Observed price2021-05-26119
Observed price2021-06-07118
Observed price2021-07-01159
Observed price2021-07-05148
Observed price2021-07-29119
Observed price2021-08-06137
Observed price2021-08-18119
Observed price2021-09-03122
Observed price2021-09-19117
Observed price2021-09-27113
Observed price2021-10-1796.8
Observed price2021-11-0296.2
Observed price2021-11-1884.3
Observed price2021-11-2280.7
Observed price2021-12-0474.0
Observed price2021-12-2081.0
Observed price2022-01-0968.6
Observed price2022-01-1765.6
Observed price2022-01-2961.3
Observed price2022-02-2254.3
Observed price2022-03-1061.9
Observed price2022-03-1460.4
Observed price2022-04-0367.8
Observed price2022-04-1163.8
Observed price2022-05-0151.1
Observed price2022-05-0943.2
Observed price2022-06-0261.0
Observed price2022-06-1459.0
Observed price2022-06-1868.0
Observed price2022-07-0468.6
Observed price2022-07-1683.5
Observed price2022-08-0980.1
Observed price2022-08-2167.8
Observed price2022-09-0662.8
Observed price2022-09-1472.2
Observed price2022-10-0465.7
Observed price2022-10-2051.3
Observed price2022-11-0948.9
Observed price2022-11-1360.7
Observed price2022-11-2155.5
Observed price2022-12-1548.3
Observed price2022-12-3140.6
Observed price2023-01-1249.1
Observed price2023-01-2049.6
Observed price2023-02-0555.5
Observed price2023-02-1351.5
Observed price2023-03-0945.6
Observed price2023-03-1745.2
Observed price2023-03-2543.5
Observed price2023-04-1045.1
Observed price2023-05-0453.1
Observed price2023-05-0856.0
Observed price2023-05-2465.9
Observed price2023-06-0564.7
Observed price2023-06-2555.9
Observed price2023-07-0754.9
Observed price2023-07-1157.6
Observed price2023-07-3156.5
Observed price2023-08-2047.7
Observed price2023-08-2850.4
Observed price2023-09-2146.1
Observed price2023-09-2545.9
Observed price2023-10-1939.8
Observed price2023-10-2738.7
Observed price2023-11-1659.2
Observed price2023-11-2072.2
Observed price2023-12-1461.8
Observed price2023-12-1865.6
Observed price2023-12-2261.5
Observed price2024-01-1962.0
Observed price2024-02-0868.8
Observed price2024-02-1276.4
Observed price2024-02-2886.7
Observed price2024-03-1176.2
Observed price2024-04-0465.1
Observed price2024-04-0864.1
Observed price2024-04-2853.5
Observed price2024-05-0657.1
Observed price2024-05-1051.2
Observed price2024-06-1562.8
Observed price2024-06-2755.4
Observed price2024-07-0553.6
Observed price2024-07-1759.5
Observed price2024-07-2956.8
Observed price2024-08-1047.3
Observed price2024-09-0745.1
Observed price2024-09-1949.5
Observed price2024-10-0545.2
Observed price2024-10-1748.3
Observed price2024-11-1051.2
Observed price2024-11-1446.9
Observed price2024-11-3051.2
Observed price2024-12-1245.8
Observed price2024-12-1644.4
Observed price2024-12-2839.9
Observed price2025-01-1338.9
Observed price2025-01-2143.5
Observed price2025-02-1039.6
Observed price2025-02-1852.2
Observed price2025-03-1043.3
Observed price2025-04-0332.7
Observed price2025-04-0732.4
Observed price2025-04-1139.3
Observed price2025-05-0534.4
Observed price2025-05-1738.9
Observed price2025-06-0237.0
Observed price2025-06-2647.6
Observed price2025-06-3048.3
Observed price2025-07-2466.1
Observed price2025-07-2863.8
Observed price2025-08-2152.8
Observed price2025-08-2951.8
Observed price2025-09-1860.7
Observed price2025-09-2261.1
Observed price2025-10-0872.8
Observed price2025-10-2071.5
Observed price2025-11-1352.4
Observed price2025-11-2149.8
Observed price2025-12-1158.1
Observed price2025-12-2356.5
Observed price2025-12-3153.4
Observed price2026-01-1255.3
Observed price2026-02-0549.5
Observed price2026-02-0948.8
Observed price2026-03-0159.1
Observed price2026-03-0958.8
Observed price2026-03-2946.7
Observed price2026-04-0649.7
Observed price2026-04-1857.4
Observed price2026-05-1648.2
Observed price2026-05-2856.4
Observed price2026-06-1351.4
Observed price2026-06-2554.2
Observed price2026-07-0760.8
Observed price2026-07-1947.3
Observed price2026-07-2746.7
Observed price2026-08-2058.1
Observed price2026-08-2857.7
Observed price2026-09-1551.8
Observed price2026-09-1652.2
Observed price2026-09-1757.3
Observed price2026-09-1856.6
Published advisor forecast2025-11-2653.3
Published advisor forecast2026-05-2762.5
Published advisor forecast2026-11-2771.0
Published advisor forecast2027-05-2780.5
Published advisor forecast2027-11-2792.1
Published advisor forecast2028-05-27105
Published advisor forecast2028-11-27118
Published advisor forecast2029-05-27132
Published advisor forecast2029-11-27145
Published advisor forecast2030-05-27158
Published advisor forecast2030-11-27170

2. Scenarios & Signals

Bull case

CRISPR Therapeutics experiences a highly successful commercial launch of for sickle cell disease and beta-thalassemia, rapidly exceeding sales forecasts due to strong physician adoption and smooth reimbursement pathways. Concurrently, its immuno- delivers compelling Phase 2/3 data, leading to at least one new therapy approval within the forecast period. The company's pioneering in-vivo programs, particularly for cardiovascular diseases, demonstrate groundbreaking efficacy and safety, causing a significant re-rating of the entire platform's value. Favorable market conditions for biotech, combined with this strong execution, attract buyout interest from major pharmaceutical players, driving the valuation to levels that reflect a multi-product, gene-editing powerhouse. The company's realistically expands as it captures significant share in multi-billion dollar markets previously served by chronic treatments.

Bear case

The commercial uptake of proves disappointing, hampered by the high price tag, complex administration logistics, and competition from alternative therapies. Payers impose stringent restrictions, limiting the addressable patient population. Simultaneously, the company's promising pipeline falters, with key immuno-oncology or cardiovascular trials failing to meet primary endpoints or revealing long-term safety concerns inherent to the CRISPR/Cas9 technology. This double blow of commercial underperformance and R&D setbacks forces the company into dilutive financing rounds to sustain operations. Persistent high interest rates and risk-off market sentiment further compress the valuation of pre-profitability biotech firms. The company struggles to move beyond its initial product, and its valuation contracts to reflect a niche, single-product entity with a high-risk, unproven pipeline.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus